Table 2.
Correlation of Parkin protein expression with clinical parameters among breast cancer patients
| S. No. | Variables | Total | Parkin Expressiona | P valueb | OR (95%CI) | ||
|---|---|---|---|---|---|---|---|
| Positive | Negative | ||||||
| 1 | Age (Years) | < 50 | 30 | 9 (30) | 21 (70) | 0.832 | 1.1255(0.4738–2.6737) |
| ≥50 | 126 | 41 (33) | 85 (67) | ||||
| 2 | Weight (Kg) | < 60 | 75 | 26 (35) | 49 (65) | 0.607 | 0.7935 (0.4046–1.5562) |
| ≥60 | 81 | 24 (30) | 57 (70) | ||||
| 3 | Tumour size (cm) | < 4’ | 73 | 29 (40) | 44 (60) | 0.060 | 0.5139 (0. 2599–1.0161) |
| ≥4 | 83 | 21 (25) | 62 (75) | ||||
| 4 | Clinical Stage | I + II | 88 | 29 (33) | 59 (67) | 0.863 | 0.9090 (0.4606–1.7941) |
| III + IV | 68 | 21 (31) | 47 (69) | ||||
| 5 | Histologicalc grade | WD | 54 | 27 (50) | 27 (50) | 0.0001* | 0.2911 (0.1435–0.5906) |
| MD + PD | 102 | 23 (22) | 79 (78) | ||||
| 6 | Lymph Node | Negative | 81 | 39 (48) | 42 (52) | < 0.0001* | 0.1851 (0.0854–0.4014) |
| Positive | 75 | 11 (15) | 64 (85) | ||||
| 7 | Menopause | Pre | 38 | 18 (47) | 20 (53) | 0.028* | 0.4134 (0.1943–0.8797) |
| Post | 118 | 32 (27) | 86 (73) | ||||
| 8 | ERd | Negative | 81 | 23 (28) | 58 (72) | 0.391 | 1.9438 (0.0190–3.7081) |
| Positive | 75 | 27 (36) | 48 (64) | ||||
| 9 | PRe | Negative | 103 | 32 (31) | 71 (69) | 0.721 | 1.1411 (0.5637–2.3099) |
| Positive | 53 | 18 (34) | 35 (66) | ||||
| 10 | Her-2f | Negative | 111 | 36 (32) | 75 (68) | 1.000 | 0.9409 (0.4463–1.9835) |
| Positive | 45 | 14 (31) | 31 (69) | ||||
| 11 | TNBCg | No | 106 | 42 (40) | 64 (60) | 0.003* | 0.2902 (0.1240–0.6793) |
| Yes | 50 | 8 (16) | 42 (84) | ||||
a Protein expression through IHC (Immunohistochemistry)
b Fisher’s exact test, *Significant Correlation (P < 0.05)
c WD Well differentiated, MD Moderately differentiated, PD Poorly differentiated
d Estrogen receptor
e Progesterone receptor
f human epidermal growth factor receptor 2
g Triple Negative breast cancer